<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03533751</url>
  </required_header>
  <id_info>
    <org_study_id>ANB020-005</org_study_id>
    <nct_id>NCT03533751</nct_id>
  </id_info>
  <brief_title>A Study Investigating the Efficacy, Safety, and PK Profile of ANB020 Administered to Adult Subjects With Moderate-to-Severe AD</brief_title>
  <acronym>ATLAS</acronym>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects With Moderate-to-Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AnaptysBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AnaptysBio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profiles of
      multiple doses of ANB020 in subjects with atopic dermatitis (AD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double blind, placebo controlled, parallel group, dose
      ranging study investigating the efficacy, safety, and pharmacokinetic profile of ANB020
      administered to adult subjects with moderate-to-severe atopic dermatitis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of ANB020 in adult patients with moderate to severe atopic dermatitis.</measure>
    <time_frame>Week 16</time_frame>
    <description>Number of participants with treatment-related adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve Investigator's Global Assessment (IGA) response of 0 (clear) or 1 (almost clear)</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve IGA Score reduction of ≥2</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in peak weekly averaged numerical rating scale (NRS) for pruritus score from baseline</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve weekly averaged NRS score reduction from baseline of ≥3</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with EASI 50 (≥50% improvement from baseline).</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with EASI 75 (≥75% improvement from baseline).</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in EASI score from baseline to clinical assessment time points prior to Week 16</measure>
    <time_frame>Through Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in EASI score from baseline.</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in percent Body Surface Area (BSA) from baseline</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in percent BSA from baseline</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Scoring Atopic Dermatitis (SCORAD) score from baseline.</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in SCORAD scores from baseline.</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Cmax - peak ANB020 concentration in serum following multiple dose administration</measure>
    <time_frame>Through study completion, Week 24</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Ctrough - trough ANB020 concentration in serum</measure>
    <time_frame>Through study completion, Week 24</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clast - last positive (quantifiable) ANB020 concentration in serum</measure>
    <time_frame>Through study completion, Week 24</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ANB020</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ANB020</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ANB020</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ANB020</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ANB020</intervention_name>
    <description>Humanized Monoclonal Antibody</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects must be 18 to 75 years of age, at the time of signing the
             informed consent.

          2. Body mass index (BMI) of 18 to 35 kg/m2 for females and 18 to 40 kg/m2 for males, and
             total body weight &gt;50 kg (110 lb).

          3. Clinically confirmed diagnosis AD.

          4. Eczema Area and Severity Index (EASI) score ≥16, body surface area (BSA) involvement
             ≥10%, and an Investigator's Global Assessment (IGA) score (5-point scale) ≥3 at
             baseline.

          5. Subjects with a history of inadequate response to topical treatment, use of systemic
             treatments to treat AD, and/or for whom topical treatments are otherwise medically
             inadvisable.

          6. Daily use of non-medicated emollient for at least 7 days prior to baseline.

        Exclusion Criteria:

          1. Treatment with topical corticosteroids, topical calcineurin inhibitors, or crisaborole
             within 2 weeks before dosing.

          2. Prior exposure to an anti-IL-33 antibody.

          3. Exposure to an investigational or licensed or other anti Th2 type cytokine or cytokine
             receptor antagonist within 16 weeks or 5 half-lives, whichever is longer.

          4. History of prior exposure to any investigational or biologic systemic treatment within
             5 half lives of the screening or is currently enrolled in another clinical study.

          5. Have received systemic treatment for AD (including systemic corticosteroids,
             immunosuppressants or immunomodulating drugs, or phototherapy or use of a tanning
             booth) within 4 weeks before screening.

          6. History of severe allergic or anaphylactic reactions to human, humanized, chimeric, or
             murine monoclonal antibodies.

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Londei, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>AnaptysBio, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian Kenney</last_name>
    <phone>858-362-6295</phone>
    <email>ANB020-005@anaptysbio.com</email>
  </overall_contact>
  <link>
    <url>http://www.anaptysbio.com</url>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2018</study_first_submitted>
  <study_first_submitted_qc>May 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2018</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

